Terry O’Reilly

603 total citations
33 papers, 464 citations indexed

About

Terry O’Reilly is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Terry O’Reilly has authored 33 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Epidemiology and 7 papers in Oncology. Recurrent topics in Terry O’Reilly's work include Liver Disease Diagnosis and Treatment (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Terry O’Reilly is often cited by papers focused on Liver Disease Diagnosis and Treatment (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Terry O’Reilly collaborates with scholars based in United States, Switzerland and Japan. Terry O’Reilly's co-authors include Heidi A. Lane, Mira Šuša, Michaela Kneissel, Reto Cortesi, Sabine Zumstein-Mecker, Σοφία Κοσσίδα, Markus Wartmann, Paul M.J. McSheehy, Peter Lassota and Ralf Brandt and has published in prestigious journals such as Blood, Gastroenterology and FEBS Letters.

In The Last Decade

Terry O’Reilly

30 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Terry O’Reilly United States	10	200	166	84	81	42	33	464
Guan-nan Jin China	12	269 1.3×	114 0.7×	76 0.9×	81 1.0×	19 0.5×	25	533
Mary‐Anne Kedda Australia	12	108 0.5×	145 0.9×	51 0.6×	83 1.0×	44 1.0×	21	449
Cristina Pérez-Ramírez Spain	14	309 1.5×	211 1.3×	70 0.8×	161 2.0×	21 0.5×	50	762
Shunji Miki Japan	9	189 0.9×	231 1.4×	47 0.6×	91 1.1×	17 0.4×	15	651
William Koss United States	9	139 0.7×	157 0.9×	38 0.5×	84 1.0×	46 1.1×	19	426
Sigrun Badrnya Austria	10	196 1.0×	90 0.5×	69 0.8×	47 0.6×	49 1.2×	16	593
Canan Cacına Türkiye	16	300 1.5×	182 1.1×	34 0.4×	41 0.5×	30 0.7×	39	567
Abdalrahman Zarzour United States	9	160 0.8×	80 0.5×	65 0.8×	30 0.4×	23 0.5×	11	505
Xianghua Yi China	14	206 1.0×	236 1.4×	59 0.7×	257 3.2×	30 0.7×	64	700
Darlene J. Elias United States	13	150 0.8×	106 0.6×	40 0.5×	43 0.5×	48 1.1×	28	503

Countries citing papers authored by Terry O’Reilly

Since Specialization

Citations

This map shows the geographic impact of Terry O’Reilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry O’Reilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry O’Reilly more than expected).

Fields of papers citing papers by Terry O’Reilly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry O’Reilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry O’Reilly. The network helps show where Terry O’Reilly may publish in the future.

Co-authorship network of co-authors of Terry O’Reilly

This figure shows the co-authorship network connecting the top 25 collaborators of Terry O’Reilly. A scholar is included among the top collaborators of Terry O’Reilly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terry O’Reilly. Terry O’Reilly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pfaff, Samuel J., Terry O’Reilly, Yan Zhang, Walter L. Olsen, & Kristopher Kuchenbecker. (2024). Scp776, A Novel IGF‐1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo‐Controlled Phase 1 Studies in Healthy Adults. Clinical Pharmacology in Drug Development. 14(1). 65–78.

Nussbaum, Jesse C., Azher Hussain, P. Butera, et al.. (2024). Single‐ and Multiple‐Dose Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, in Healthy Adults. The Journal of Clinical Pharmacology. 64(8). 1023–1029. 4 indexed citations

O’Reilly, Terry, et al.. (2023). A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clinical Pharmacology in Drug Development. 12(3). 236–248. 1 indexed citations

Wong, Shekman, Cecile M. Krejsa, Dana Lee, et al.. (2022). Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects. Clinical Pharmacology in Drug Development. 11(5). 640–653. 2 indexed citations

Lester, R. J. G., et al.. (2021). P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 Study. The American Journal of Gastroenterology. 116(1). S7–S7. 1 indexed citations

O’Reilly, Terry, et al.. (2020). Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults. Toxins. 12(8). 511–511. 10 indexed citations

Liu, Yang, Terry O’Reilly, Francheska Colón‐González, et al.. (2020). Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants. Clinical Pharmacology in Drug Development. 9(4). 466–475. 3 indexed citations

Fox, Jonathan C., Jennifer Hellawell, Terry O’Reilly, et al.. (2019). First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development. 9(1). 115–129. 41 indexed citations

Marshall, William L., Hwa-ping Feng, Luzelena Caro, et al.. (2017). No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. European Journal of Clinical Pharmacology. 73(5). 593–600. 7 indexed citations

10.

Nguyen, Linh T., et al.. (2015). Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. The Journal of Clinical Pharmacology. 55(9). 1012–1023. 66 indexed citations

11.

Feng, Hwa-ping, et al.. (2014). Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. European Journal of Clinical Pharmacology. 70(9). 1107–1113. 12 indexed citations

12.

Gisclon, L. G., Angela Bowen, Terry O’Reilly, et al.. (2011). Bioequivalence of a Newly Developed 17β-Estradiol Tablet versus an Identical Reference Formulation. Arzneimittelforschung. 50(10). 910–914.

13.

O’Reilly, Terry, Paul M.J. McSheehy, Markus Wartmann, et al.. (2010). Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anti-Cancer Drugs. 22(1). 58–78. 57 indexed citations

14.

O’Reilly, Terry, Markus Wartmann, Saveur-Michel Maira, et al.. (2004). Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemotherapy and Pharmacology. 55(4). 307–317. 24 indexed citations

15.

Kneissel, Michaela, Reto Cortesi, Sabine Zumstein-Mecker, et al.. (2004). Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 35(5). 1144–1156. 127 indexed citations

16.

O’Reilly, Terry, et al.. (1998). Unique chemical reactivity of His‐21 of CRM‐197, a mutated diphtheria toxin. FEBS Letters. 427(3). 362–366. 4 indexed citations

17.

Bucana, C, Robert Radinsky, Zhongyun Dong, et al.. (1996). Maintenance of Intestinal Epithelium Structural Integrity and Mucosal Leukocytes During Chemotherapy by Oral Administration of Muramyl Tripeptide Phosphatidylethanolamine. Cancer Biotherapy and Radiopharmaceuticals. 11(6). 363–371. 4 indexed citations

18.

MacMathúna, Padraic, Terry O’Reilly, Dermot Kelleher, et al.. (1987). The effect of calcium channel blockade with nifedipine on splanchnic and systemic haemodynamics in cirrhosis. Alimentary Pharmacology & Therapeutics. 1(6). 639–642. 2 indexed citations

19.

O’Reilly, Terry, et al.. (1987). Comparison of the spectrophotometric and high-performance liquid chromatographic analysis of Indocyanine Green in estimating systemic clearance in patients with chronic liver disease. Journal of Chromatography B Biomedical Sciences and Applications. 417(1). 190–196. 5 indexed citations

20.

O’Reilly, Terry, et al.. (1986). Combined Vasodilation and β-Adrenergic Blockade Therapy in Portal Hypertension. Clinical Science. 71(s15). 74P–75P. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact